User talk:Shaze

Welcome!

Hello, Shaze! Welcome to Wikipedia! Thank you for your contributions. You may benefit from following some of the links below, which will help you get the most out of Wikipedia. If you have any questions you can ask me on my talk page, or place {{helpme}} on your talk page and ask your question there. Please remember to sign your name on talk pages by clicking

or by typing four tildes "~~~~"; this will automatically produce your name and the date. If you are already excited about Wikipedia, you might want to consider being "adopted" by a more experienced editor or joining a WikiProject to collaborate with others in creating and improving articles of your interest. Click here for a directory of all the WikiProjects. Finally, please do your best to always fill in the edit summary field when making edits to pages. Happy editing! LefcentrerightTalk (plz ping) 14:12, 17 April 2020 (UTC)[reply]

Getting Started
Contributing to Wikipedia • Tutorial • Your first article The five pillars of Wikipedia • Simplified ruleset How to: edit a page • upload an image
Getting Help
Frequently Asked Questions Directories and indexes Where to: ask questions • make requests Tip of the day Request administrator attention
Policies and Guidelines
Neutral point of view • Reliable sources Verifiability • Citing sources • No original research What Wikipedia is not • Biographies of living persons Manual of Style (Simplified) • Three-revert rule Copyrights • Non-free content • Image use policy External links • Spam • Vandalism • Sock puppetry Deletion policy • Conflict of interest • Notability

The Community
Community Portal • Adopt-a-user program Assume good faith • Civility • Etiquette No personal attacks • Resolving disputes Build consensus • Village pump IRC channels • Mailing lists The Signpost (Wikipedia's newspaper)
Things to do
Be bold in editing • Help develop an article Maintenance • Peer review • Requested articles Join a WikiProject • Translating articles Cleaning up: General • Spam • Vandalism
Miscellaneous
Categories • Disambiguity • Stubs User pages • Talk pages Useful templates • Tools • User scripts

Clinical Trials

Hello @Shaze:. Wikipedia strongly encourages secondary sources for biomedical information. One of your references is a primary source. There are many clinical trials currently being conducted for COVID-19. This is a rapidly evolving area, with information outdated in a day or less.

For instance, lopinavir/ritonavir which you mention, has been found to be ineffective - well designed study published in highly reputable The New England Journal of Medicine ^[1]

Also, chloroquine or hydroxychloroquine has indications of toxicity and being ineffective ^[2] ^[3] ^[4] ^[5]

More drug details can be found in the specific article - Solidarity Trial, which is linked in the first sentence.

I will thus use a secondary source(s) and move the specific drug info. because the purpose of the article is not to summarise the arms of an ongoing clinical trial, whose results have not been reported even in primary literature. Readers might think the clinical trial medications/drugs you mention are legitimate therapeutic options, when new studies show otherwise. If you disagree, please do not revert my edits, but instead use the article's talk page.

@Doc James: @Jeandré du Toit: @Discott: @Bobbyshabangu: @Netha Hussain: @5 albert square: @Discott:

Ear-phone (talk) 00:46, 18 April 2020 (UTC)[reply]

Not sure why the ping? Doc James (talk · contribs · email) 00:48, 18 April 2020 (UTC)[reply]

Hello @Doc James: because you're arguably the most skilled Wikipedian regarding these matters. Your input would assist. Thank you. Ear-phone (talk) 01:01, 18 April 2020 (UTC)[reply]

I don't exactly understand what the whole issue is about, but my stand is to use secondary sources, systematic reviews and meta analyses wherever possible in all medical articles. Solidarity Trial is ongoing and it is too early to say if any of the drugs used in the trial are effective or not. --Netha (talk) 08:39, 18 April 2020 (UTC)[reply]

@Netha: I'm happy for the content to be reworded in order to add explicit caution in case a reader misunderstands and wants to self-dose, but I think the point's been missed. The purpose of what I added was to report on what clinical trials are being done in South Africa as well as related clinical responses, not the outcomes of the trials. Your points imply that somehow I was endorsing those drugs which is not to be found or even implied in what I wrote. It is a fact that the initial drugs that were in the test are the ones that I wrote. I really don't think that this can be disputed and if you are reporting what actually happened in South Africa, you have to report that, whether or not the drugs turn out to be successful or safe. All that was reported is that the trial was happening and I think this is a good reference for it. I would agree that if we were reporting the *outcome* of the trial it would not be a good reference. The Solidarity Trial is an important and relevant international medical response, and it is relevant to include South African contributions on this page. So I strongly disagree with the decision to cut it on those grounds, which I think are wrong. If the decision had been made on more editorial grounds -- that it was unnecessary detail in the context of an article which is likely to become very big -- I am happy to live that that.

Hello @Shaze:. I am the one who made the changes. I pinged @Netha Hussain:, a physician, as the creator of the Solidarity Trial article. So far, the consensus is that the more specific clinical trial details are unnecessary on a page that is trying to capture a whole country response rather than describe medications under investigations by a particular trial. There is a whole Wikipedia article dedicated to the trial. Ear-phone (talk) 12:58, 19 April 2020 (UTC)[reply]

References

^ Cao, Bin; Wang, Yeming; Wen, Danning; Liu, Wen; Wang, Jingli; Fan, Guohui; Ruan, Lianguo; Song, Bin; Cai, Yanping; Wei, Ming; Li, Xingwang (2020-03-18). "A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19". New England Journal of Medicine. doi:10.1056/NEJMoa2001282. PMC 7121492. PMID 32187464.{{cite journal}}: CS1 maint: PMC format (link)
^ Borba, Mayla Gabriela Silva; Val, Fernando de Almeida; Sampaio, Vanderson Sousa; Ara&amp, Marcia Almeida; Alexandre, Uacutejo; Melo, Gisely Cardoso; Brito, Marcelo; Mour&amp, Maria Paula Gomes; atildeo; Jos& Sousa, eacute Diego Brito (2020-04-16). "Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)". medRxiv: 2020.04.07.20056424. doi:10.1101/2020.04.07.20056424.
^ Taccone, Fabio S; Gorham, Julie; Vincent, Jean-Louis (2020-04). "Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base". The Lancet Respiratory Medicine. doi:10.1016/s2213-2600(20)30172-7. ISSN 2213-2600. PMC 7159849. PMID 32272081. {{cite journal}}: Check date values in: |date= (help)CS1 maint: PMC format (link)
^ Tang, Wei; Cao, Zhujun; Han, Mingfeng; Wang, Zhengyan; Chen, Junwen; Sun, Wenjin; Wu, Yaojie; Xiao, Wei; Liu, Shengyong; Chen, Erzhen; Chen, Wei (2020-04-14). "Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial". medRxiv: 2020.04.10.20060558. doi:10.1101/2020.04.10.20060558.
^ Magagnoli, Joseph; Narendran, Siddharth; Pereira, Felipe; Cummings, Tammy; Hardin, James W.; Sutton, S. Scott; Ambati, Jayakrishna (2020-04-21). "Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19". medRxiv: 2020.04.16.20065920. doi:10.1101/2020.04.16.20065920.

CoViD-19 Gauteng stats?

Re File:Gauteng-covid19.svg, can you add your sources for this? I'd like to use the most recent figures for the map. -- Jeandré, 2020-05-15t13:03z @Jeandré: Done

Thanks for CoViD-19 charts.

	The South African Barnstar of National Merit
	Thanks for your exceptional contributions to the South African CoViD-19 article with the charts.
	_{this WikiAward was given to Shaze by -- Jeandré, 2020-12-31t07:17z on 07:17, 31 December 2020 (UTC)}[reply]

File:Za-covid-actives.svg as-of and comment dates.

Re: the as-of and update dates at e.g. https://wiki.riteme.site/w/index.php?title=COVID-19_pandemic_in_South_Africa&diff=1043650761&oldid=1043621545 and https://commons.wikimedia.org/wiki/File:Za-covid-actives.svg - shouldn't it be for the day before, because data for 2021-09-11 can't be available at the upload date and time of 2021-09-11T06:50:07. So shouldn't the legend1 and upload Comment date be for 2021-09-10? -- Jeandré, 2021-09-16t10:18z

South African Discord

Interested in joining the South African Wikipedia Discord?

If you are interested in a joining, please visit Wikipedia:Meetup/South Africa/Discord for more Infomation or click the button below

Everyone in Southern Africa is Welcome, for any technical issues or questions about Discord, Please ask User:TapticInfo on his talk page

Join Server

Hi, I would like to invite you to the Wikimedia South Africa Discord Server.

Discord allows instant text, voice and video communication and is used for all the South Africa Wikipedians monthly meetups.

See Wikipedia:Meetup/South Africa, the next one is on 26 February 2022 at 10:00am SAST Wikipedia:Meetup/South_Africa/South_Africa_15

TapticInfo (talk) 10:14, 31 January 2022 (UTC)[reply]

ArbCom 2022 Elections voter message

Hello! Voting in the 2022 Arbitration Committee elections is now open until 23:59 (UTC) on Monday, 12 December 2022. All eligible users are allowed to vote. Users with alternate accounts may only vote once.

The Arbitration Committee is the panel of editors responsible for conducting the Wikipedia arbitration process. It has the authority to impose binding solutions to disputes between editors, primarily for serious conduct disputes the community has been unable to resolve. This includes the authority to impose site bans, topic bans, editing restrictions, and other measures needed to maintain our editing environment. The arbitration policy describes the Committee's roles and responsibilities in greater detail.

If you wish to participate in the 2022 election, please review the candidates and submit your choices on the voting page. If you no longer wish to receive these messages, you may add {{NoACEMM}} to your user talk page. MediaWiki message delivery (talk) 00:23, 29 November 2022 (UTC)[reply]

ArbCom 2024 Elections voter message

Hello! Voting in the 2024 Arbitration Committee elections is now open until 23:59 (UTC) on Monday, 2 December 2024. All eligible users are allowed to vote. Users with alternate accounts may only vote once.

The Arbitration Committee is the panel of editors responsible for conducting the Wikipedia arbitration process. It has the authority to impose binding solutions to disputes between editors, primarily for serious conduct disputes the community has been unable to resolve. This includes the authority to impose site bans, topic bans, editing restrictions, and other measures needed to maintain our editing environment. The arbitration policy describes the Committee's roles and responsibilities in greater detail.

If you wish to participate in the 2024 election, please review the candidates and submit your choices on the voting page. If you no longer wish to receive these messages, you may add {{NoACEMM}} to your user talk page. MediaWiki message delivery (talk) 00:08, 19 November 2024 (UTC)[reply]

[1] Cao, Bin; Wang, Yeming; Wen, Danning; Liu, Wen; Wang, Jingli; Fan, Guohui; Ruan, Lianguo; Song, Bin; Cai, Yanping; Wei, Ming; Li, Xingwang (2020-03-18). "A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19". New England Journal of Medicine. doi:10.1056/NEJMoa2001282. PMC 7121492. PMID 32187464.{{cite journal}}: CS1 maint: PMC format (link)

[2] Borba, Mayla Gabriela Silva; Val, Fernando de Almeida; Sampaio, Vanderson Sousa; Ara&amp, Marcia Almeida; Alexandre, Uacutejo; Melo, Gisely Cardoso; Brito, Marcelo; Mour&amp, Maria Paula Gomes; atildeo; Jos& Sousa, eacute Diego Brito (2020-04-16). "Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)". medRxiv: 2020.04.07.20056424. doi:10.1101/2020.04.07.20056424.

[3] Taccone, Fabio S; Gorham, Julie; Vincent, Jean-Louis (2020-04). "Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base". The Lancet Respiratory Medicine. doi:10.1016/s2213-2600(20)30172-7. ISSN 2213-2600. PMC 7159849. PMID 32272081. {{cite journal}}: Check date values in: |date= (help)CS1 maint: PMC format (link)

[4] Tang, Wei; Cao, Zhujun; Han, Mingfeng; Wang, Zhengyan; Chen, Junwen; Sun, Wenjin; Wu, Yaojie; Xiao, Wei; Liu, Shengyong; Chen, Erzhen; Chen, Wei (2020-04-14). "Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial". medRxiv: 2020.04.10.20060558. doi:10.1101/2020.04.10.20060558.

[5] Magagnoli, Joseph; Narendran, Siddharth; Pereira, Felipe; Cummings, Tammy; Hardin, James W.; Sutton, S. Scott; Ambati, Jayakrishna (2020-04-21). "Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19". medRxiv: 2020.04.16.20065920. doi:10.1101/2020.04.16.20065920.

[1]

[2]

[3]

[4]

[5]